Eli Lilly and Company’s next step in its strategy for COVID-19 monoclonal antibodies is about doubles: The timing of when it will seek an emergency use authorization for its two-antibody combo regimen depends on two factors – safety data and manufacturing confidence.
Lilly’s EUA Timeline For COVID-19 Combo Antibody Depends On Safety Data, Manufacturing
Single neutralizing antibody moves to US FDA with data showing reduced hospitalization, while Lilly’s EUA filing for two-antibody combo awaits safety data and more certainty about production capabilities.
